Denis DELVAL is Appointed CEO of LFB SA
On December 20 th , a decree from the President of France was published in Le Journal Officiel* appointing Denis DELVAL CEO of LFB S.A. This decree follows the General Meeting of LFB SA and the meeting of its Board of Directors, which both took place on December 4 th , 2017.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171221005345/en/
Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th , following Christian BÉCHON and Denis SOUBEYRAN’s departures.
A graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy, Denis DELVAL has a deep understanding of the pharmaceutical industry. He has held important marketing, sales and strategic positions in France, Europe and worldwide and has managed international partnerships within various pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was appointed General Manager of ALK France. In 2012, he also became Senior Vice President of the Danish pharmaceutical company specialized in allergy immunotherapy treatments. Denis DELVAL lectures at ESSEC business school and has also been Chairman of Lecrip.org, a healthcare think tank.
“I am proud to be appointed as CEO of LFB Group and to work for this company operating in a strategic sector. LFB produces therapeutics that are essential for the lives of thousands of patients, particularly in the rare disease field. I am fully aware of the challenges ahead and look forward to unleashing energies to make this pharmaceutical company successful in France and internationally.”
* The Official Journal of the French Republic.
About LFB Group
LFB is a biopharmaceutical group that develops, manufactures, and markets medicinal products derived from living matter for the treatment of serious and often rare diseases in several major therapeutic fields, including Hemostasis, Immunology and Intensive Care. LFB is the leading manufacturer of plasma-derived medicinal products in France and 7 th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies. Through its constant research efforts, the LFB group implements a growth strategy to expand its activities on international markets. Today, LFB currently markets its products in almost 60 countries around the world with a global turnover of €518.9 million in 2016. LFB group employs more than 2300 people worldwide.
Sandrine Charrières, Tel : +33-(0)1-6982-7280
Executive VP Corporate Communications
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
KOZA-ALTIN13.7.2018 18:00 | pressemeddelelse
Koza Altin Welcomes Court’s Rejection of Akin Ipek’s Share Purchase Agreement
MINDBREEZE13.7.2018 17:29 | pressemeddelelse
Mindbreeze Positioned in the Leaders Quadrant of the Gartner’s 2018 Magic Quadrant for Insight Engines
H.I.G.-CAPITAL13.7.2018 16:08 | pressemeddelelse
H.I.G. Capital Announces the Sale of Kondor
VISA-INC.13.7.2018 11:02 | pressemeddelelse
Contactless Technology Powers Fifty Percent of Purchases at 2018 FIFA World Cup Russia™
FL-AERSALE12.7.2018 21:20 | pressemeddelelse
Brazil Approves AerSafe for Airbus 321 Aircraft to Comply with Fuel Tank Flammability Reduction Rule
NJ-ADENTS12.7.2018 20:22 | pressemeddelelse
Blockchain-based Adents NovaTrack Issues Token to Standardize Access to Comprehensive Supply Chain Traceability
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum